US Stocks: Apellis shares double on Biogen's $5.6 billion buyout plan
- Postato il 31 marzo 2026
- Di Business News Today
- 3 Visualizzazioni
US Stocks: Apellis shares double on Biogen's $5.6 billion buyout plan
Biogen will buy Apellis Pharmaceuticals for about $5.6 billion, adding a promising kidney disease drug to broaden its rare-disease portfolio amid efforts to diversify beyond its slowing multiple sclerosis franchise.
